Dr. Nagourney's Blog


Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

Drug Resistant Acute Myeloid Leukemia Meets Its Match
By Robert A. Nagourney, MD
Among the diseases that hematologist-oncologists regularly treat, acute myelogenous leukemia (AML) can be viewed as a qualified success. With appropriate (induction and consolidation) therapy, 40-50% of adults with this disease can achieve...
Victories in Acute Leukemia - Opportunities to Expand the Horizon
By Robert A. Nagourney, MD
The March 29, 2016 Wall Street Journal  reported a 23-year-old man with acute myeloid leukemia (AML). Using genomic (DNA)...
A New Use for One of the Oldest “New” Drugs - Sorafenib
By Robert A. Nagourney, MD
With the profusion of new targeted agents entering the clinical arena, a report from the American Society of Hematology bears...
A Tale of Two Trials - AML & Stage 3 Non Small Cell Lung Cancer
By Robert A. Nagourney, MD
As I read through the November 10 issue of the Journal of Clinical Oncology there were two very different but highly...

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.